![Brainsway - logo](https://img.medicalexpo.com/images_me/logo-p/L83634.gif)
Catalog excerpts
![Brainsway Transcran:brochure USA - 1](https://img.medicalexpo.com/pdf/repository_me/83634/brainsway-transcran-brochure-usa-137878_1m.jpg)
A NEW ERA: DEEP YET NON-INVASIVE BRAIN STIMULATION T he patented breakthrough technology of Brainsway TM launches a new era in the treatment of brain disorders. Brainsway offers a non-invasive yet highly effective treatment that activates deep brain structures. This is achieved using directed electromagnetic fields which generate excitation or inhibition of neurons deep inside the brain. The technology has been enthusiastically embraced by the international academic community, with over 60 clinical studies in leading institutions worldwide. U nique Patented Coil Structure B rainsway's Deep TMS (Deep Transcranial Magnetic Stimulation) technology is based on the H Coil, featuring a novel patented structure which maximizes electrical stimulation of deep brain regions. Unique features of the coil design include: • Coil elements tangential to the head and close to target brain regions Flexible base suited to head shape • Convergence of numerous electric pulses from • various directions Coil elements parallel to target bundles • Location of return paths of electrical impulses • remote from target area B rainsway technology is based on a patent registered by the U.S. National Institutes of Health (NIH). Brainsway has an exclusive license from the NIH for both the patent and the technology.
Open the catalog to page 1![Brainsway Transcran:brochure USA - 2](https://img.medicalexpo.com/pdf/repository_me/83634/brainsway-transcran-brochure-usa-137878_2m.jpg)
Deeper Stimulation Electric Field of F8 Coil Electric Field of Deep TMS H1 Coil Electric Fields Generated by Figure 8 Coil vs. Deep TMS H1 Coil1 P roven Efficacy S tudies show that stimulation of deeper (ventral) PFC structures significantly enhances antidepressant effects. The FDA has cleared Brainsway's Deep TMS technology for treatment of a wide range of Depression patients, from mild to severe cases, who did not benefit from antidepressants in the current depressive episode 2. The indication is based on a 16-week double blind placebo controlled study enrolling over 230 subjects...
Open the catalog to page 2